ArticleNature biotechnology2025
Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms.
Erratum issuedAbstract read
In one paragraph
Article in Nature biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Technical review of artificial intelligence in TCR-T therapy.Journal of the National Cancer Center · 2026Review
- Modeling TCR-Epitope Recognition Specificity: What We Should Learn to Succeed.Immunological reviews · 2026Review
- Deciphering small sequence differences in T cell receptor-antigen pairing.Nature communications · 2026Article
- Generation of T cells with reduced off-target cross-reactivities by engineering co-signalling receptors.Nature biomedical engineering · 2026Article
- Algorithm guided personalized T cell therapy: machine learning unlocks next generation TCR engineered immunotherapy.Pharmacological reports : PR · 2026Review
- cloneXplorer: A high-throughput clone discovery platform based on conical microwell arrays.bioRxiv : the preprint server for biology · 2026Article
- Tumor reactivity assessment using clonal expression reveals tumor reactive CD8Frontiers in immunology · 2026Article
- Nanobioconjugate Trispecific Antibody Augments Antitumor Immunity of Triple Negative Breast Cancer.International journal of nanomedicine · 2026Article
- Multivalently engineered glyco-nanoplatforms for targeted therapy and diagnostics.Chemical science · 2025Review
- Harnessing TCR repertoires: predictive insights and therapeutic monitoring in cancer immunotherapy.Immuno-oncology technology · 2025Review
- Single-cell insights into the role of T cells in B-cell malignancies.FEBS letters · 2025Review
- SURROGATE SELECTION OVERSAMPLES EXPANDED T CELL CLONOTYPES.The annals of applied statistics · 2025Article
- Constructing the cure: engineering the next wave of antibody and cellular immune therapies.Journal for immunotherapy of cancer · 2025Review
- Regulatory T cells define affinity thresholds for CD8NPJ vaccines · 2025Article
- Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms.Nature biotechnology · 2025Article
- Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.Nature communications · 2025Article
- Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies.Theranostics · 2025Review
- Review
- Next-generation combination approaches for immune checkpoint therapy.Nature immunology · 2024Review
- Predicting Antigen-Specificities of Orphan T Cell Receptors from Cancer Patients with TCRpcDist.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
25 authors.
Rémy PétremandLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-7629-7336
Johanna ChiffelleLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-8312-2681
Sara BobisseLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.
Marta A S PerezLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.
Julien SchmidtLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.
Marion ArnaudLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-0534-2379
David BarrasLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-8985-4704
Maria Lozano-RabellaLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-6304-3919
Raphael GenoletLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-9335-3945
Christophe SauvageLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.
Damien SaugyLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.
Alexandra MichelLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.
Anne-Laure Huguenin-BergenatLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.
Charlotte CaptLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.
Jonathan S MooreDepartment of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Swiss Cancer Center Leman, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-7586-671X
Claudio De VitoDivision of Clinical Pathology, Department of Diagnostics, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
S Intidhar Labidi-GalyDepartment of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Swiss Cancer Center Leman, Geneva, Switzerland.
Lana E KandalaftLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-1575-6674
Denarda Dangaj LanitiLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.
Michal Bassani-SternbergLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-1934-954X
Giacomo OliveiraDana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7435-5603
Catherine J WuDana-Farber Cancer Institute, Boston, MA, USA.
George CoukosLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-8813-7367
Vincent ZoeteLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-2336-6537
Alexandre HarariLudwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland. alexandre.harari@chuv.ch.ORCID http://orcid.org/0000-0002-1055-2090
Funding
No grant is acknowledged in the PubMed record.
Abstract
A central challenge in developing personalized cancer cell immunotherapy is the identification of tumor-reactive T cell receptors (TCRs). By exploiting the distinct transcriptomic profile of tumor-reactive T cells relative to bystander cells, we build and benchmark TRTpred, an antigen-agnostic in silico predictor of tumor-reactive TCRs. We integrate TRTpred with an avidity predictor to derive a combinatorial algorithm of clinically relevant TCRs for personalized T cell therapy and benchmark it in patient-derived xenografts.
Indexed as
AlgorithmsImmunotherapy, AdoptiveNeoplasmsPrecision MedicineReceptors, Antigen, T-CellT-LymphocytesAnimalsCell- and Tissue-Based TherapyHumansMiceReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.